BioCryst Pharmaceuticals Surges on Strong Financial Performance

BioCryst Pharmaceuticals shares are trading higher after the company reported strong Q1 financial results with a 51% increase in ORLADEYO net revenue and raised its full-year revenue guidance, alongside plans to achieve profitability in 2025, a year ahead of schedule.